
## Simon Tremblay

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7693852/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. American Journal of Transplantation, 2017, 17, 432-442.	4.7	109
2	Impact of a Pharmacist‣ed Warfarin Selfâ€Management Program on Quality of Life and Anticoagulation Control: A Randomized Trial. Pharmacotherapy, 2012, 32, 871-879.	2.6	63
3	A prospective, iterative, adaptive trial of carfilzomib-based desensitization. American Journal of Transplantation, 2020, 20, 411-421.	4.7	47
4	Safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, a type 2 anti-CD20 monoclonal antibody for the desensitization of candidates for renal transplant. American Journal of Transplantation, 2019, 19, 3035-3045.	4.7	44
5	Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial. PLoS Medicine, 2017, 14, e1002428.	8.4	29
6	Addition of Rifampin to Vancomycin for Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: What Is the Evidence?. Annals of Pharmacotherapy, 2013, 47, 1045-1054.	1.9	21
7	Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells. American Journal of Transplantation, 2020, 20, 399-410.	4.7	18
8	Successful Simultaneous Liver-Kidney Transplantation in the Presence of Multiple High-Titered Class I and II Antidonor HLA Antibodies. Transplantation Direct, 2016, 2, e121.	1.6	17
9	Plasma cell targeting to prevent antibody-mediated rejection. American Journal of Transplantation, 2020, 20, 33-41.	4.7	16
10	Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations. AAPS Journal, 2017, 19, 1332-1347.	4.4	15
11	A phase Ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end-stage renal disease. Clinical Transplantation, 2018, 32, e13155.	1.6	15
12	Targeting Plasma Cells with Proteasome Inhibitors: Principles from Primates. Journal of the American Society of Nephrology: JASN, 2017, 28, 1951-1953.	6.1	14
13	lgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. New England Journal of Medicine, 2017, 377, 1692-1694.	27.0	14
14	mTOR Inhibitor Therapy Diminishes Circulating CD8+ CD28â^ Effector Memory T Cells and Improves Allograft Inflammation in Belatacept-refractory Renal Allograft Rejection. Transplantation, 2020, 104, 1058-1069.	1.0	13
15	Absence of the Effect of Pretransplant Body Mass Index on Post Kidney Transplant Outcomes. Progress in Transplantation, 2016, 26, 183-190.	0.7	10
16	Reducing Donor-specific Antibody During Acute Rejection Diminishes Long-term Renal Allograft Loss: Comparison of Early and Late Rejection. Transplantation, 2020, 104, 2403-2414.	1.0	6
17	Discharge medication procurement and education after kidney transplantation. Clinical Transplantation, 2019, 33, e13627.	1.6	3
18	Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients. Pharmacotherapy, 2019, 39, 564-575.	2.6	2

#	Article	IF	CITATIONS
19	Reply to "Fluctuation Does Not Mean Variability: A Pharmacokinetic Point of View― American Journal of Transplantation, 2017, 17, 1693-1693.	4.7	0
20	Immunosuppression for Liver Retransplantation: Babel Revisited. Transplantation, 2021, 105, 1658-1659.	1.0	0